Rebamipide: Benefits, Uses, and Side Effects

Rebamipide is a mucosal-protective drug that works by boosting the body’s own defenses along the lining of the gut and, in eye-drop form, the surface of the eye. Originally developed in Japan in the 1990s for treating gastric ulcers, it has since found roles in preventing painkiller-related stomach damage, helping clear Helicobacter pylori infections, managing dry eye disease, and reducing radiation-induced mouth sores. Its mechanism is unusual: rather than suppressing acid like a proton-pump inhibitor, rebamipide stimulates the production of protective mucus, scavenges tissue-damaging free radicals, and dials down local inflammation. That profile explains why researchers keep finding new places in the body where it may be useful, and why the drug’s story is broader than a single indication might suggest.

How Rebamipide Works

Most drugs for stomach problems either block acid production or neutralize acid once it is there. Rebamipide takes a different approach. It encourages cells to produce more prostaglandins, which are signaling molecules that help maintain the stomach’s protective mucus layer and blood flow. It also ramps up mucin production, the gel-like substance that lines mucosal surfaces and keeps digestive juices from eating into tissue. On top of that, it acts as an oxygen free-radical scavenger, meaning it mops up the reactive molecules that damage cells during inflammation.¹²

At the molecular level, rebamipide suppresses a major inflammation pathway called NF-κB. When this pathway is overactive, cells churn out inflammatory signals such as TNF-α and interleukin-8. Rebamipide blocks the chain of events that activates NF-κB, which reduces the downstream production of those inflammatory molecules.³⁴ This anti-inflammatory action is what makes rebamipide relevant far beyond the stomach. The same NF-κB pathway drives tissue damage in the eyes, the mouth, and potentially even in spinal discs.

Protecting the Stomach From Painkillers

Non-steroidal anti-inflammatory drugs like ibuprofen, naproxen, and diclofenac are some of the most commonly used painkillers worldwide, and stomach damage is one of their best-known downsides. Standard practice is to co-prescribe a proton-pump inhibitor or misoprostol to protect the stomach lining. Rebamipide has been studied as an alternative or addition to those strategies, with mixed but generally encouraging results.

In a randomized trial of healthy volunteers given ibuprofen, those who also took rebamipide had significantly less stomach mucosal injury and no gastric ulcers, compared with three ulcers in the placebo group. The researchers linked the protection to rebamipide’s ability to maintain blood flow in the stomach lining, which painkillers tend to reduce.⁵ A larger multicenter trial comparing rebamipide head-to-head with misoprostol in patients on long-term painkiller therapy found the two drugs prevented ulcers equally well.⁶ A separate 12-week study reinforced that finding: gastric ulcer rates were about 20% in both the rebamipide and misoprostol groups, but patients on rebamipide reported significantly fewer gastrointestinal symptoms and used less antacid.⁷

The picture is not uniformly positive, though. A trial using naproxen found that rebamipide at 200 mg per day did not protect against stomach or duodenal damage in healthy volunteers.⁸ A systematic review concluded that rebamipide was roughly equal to, not superior to, standard strategies including proton-pump inhibitors and misoprostol for preventing painkiller-induced gut damage.⁹ The practical takeaway is that rebamipide is a genuine option for stomach protection alongside painkillers, especially where misoprostol’s side effects (cramping and diarrhea) are a problem, but it is not necessarily a step up from what is already available.

Where Rebamipide May Have an Edge: Small Intestine Damage

Proton-pump inhibitors are good at protecting the stomach, but they do nothing for the small intestine, which painkillers can also damage. This is a blind spot in standard gastroprotection, because small bowel injuries often go undetected unless someone happens to swallow a capsule endoscopy camera. Rebamipide’s mucosal-protective action is not limited to the stomach, and several trials have tested whether it can reduce painkiller damage further down the digestive tract.

A double-blind trial gave healthy volunteers diclofenac for two weeks, with or without rebamipide. Capsule endoscopy showed that rebamipide had the potential to reduce the intensity of small intestinal injuries caused by the painkiller.¹⁰ Aspirin tells a similar story. In a placebo-controlled trial, rebamipide significantly prevented mucosal breaks in the ileum (the end of the small intestine) after one and four weeks of aspirin use.¹¹ For people already taking long-term aspirin who had moderate-to-severe small intestinal damage, eight weeks of high-dose rebamipide significantly decreased the number of mucosal breaks and improved damage severity scores, with good tolerability.¹²

This is arguably rebamipide’s most distinctive selling point in gastroenterology. Millions of people take daily low-dose aspirin for heart protection and have no practical option to shield their small intestine from injury. Rebamipide may fill that gap, although the evidence still comes from relatively small trials and larger confirmatory studies would strengthen the case.

Boosting H. pylori Eradication

H. pylori is the bacterium behind most stomach ulcers and a recognized risk factor for gastric cancer. Clearing it usually requires a combination of antibiotics plus an acid-suppressing drug. Adding rebamipide to that regimen appears to improve the odds of successfully wiping out the infection. A meta-analysis found that eradication rates were roughly 73% with rebamipide versus about 61% without it in dual-therapy regimens, amounting to meaningfully better odds of success.¹³

A more recent umbrella review pooling data from multiple meta-analyses confirmed the benefit. The overall pooled eradication rate was about 83% in the rebamipide group versus 73% in controls. When looking specifically at triple therapy regimens (the most common approach), adding rebamipide pushed eradication rates above 90%, compared with about 82% without it.¹⁴ The thinking is that a healthier, better-protected mucosal surface may help antibiotics work more effectively against the bacterium. That same umbrella review also found that rebamipide improved ulcer healing after endoscopic procedures and reduced dyspeptic symptoms, suggesting broad utility as an add-on in gastrointestinal care.

Dry Eye Disease

Rebamipide’s ability to stimulate mucin production makes it a natural fit for dry eye, where one of the core problems is a deficient or unstable tear film. In Japan, a 2% rebamipide ophthalmic suspension (brand name Mucosta) has been available since 2012 and is widely used as a frontline therapy.¹⁵ The mechanism in the eye mirrors what happens in the gut: rebamipide increases the number of mucin-producing goblet cells in the conjunctiva (the clear membrane over the white of the eye) and boosts their output of MUC5AC, a key mucin that stabilizes the tear film.¹⁶¹⁷

Clinical trials back up the lab findings. A phase II study found that both 1% and 2% rebamipide eye drops significantly improved corneal staining scores (a measure of surface damage), conjunctival staining, tear break-up time, and all five dry-eye symptom scores compared with placebo.¹⁸ A later multicenter trial of a clear solution formulation confirmed that 1% and 2% concentrations both improved tear break-up time, corneal staining, and Schirmer test values (a measure of tear production) over 12 weeks, whereas placebo did not show the same gains.¹⁹

When compared with 0.1% sodium hyaluronate (a standard lubricant eye drop), 2% rebamipide was not only noninferior but actually superior for conjunctival staining, and patients reported significantly better overall impressions of treatment. About two thirds of patients rated rebamipide as improved or markedly improved, versus about a third for sodium hyaluronate.²⁰ Diquafosol, another mucin-stimulating eye drop popular in Asia, performs comparably to rebamipide for signs and symptoms, though diquafosol appears better at boosting aqueous tear secretion specifically.²¹

Temporary Blurred Vision After Instillation

One practical downside of rebamipide eye drops that patients notice right away is transient blurred vision. The suspension form is opaque white, and immediately after instillation it increases forward light scatter significantly compared with other dry eye drops. The blur clears as the drug disperses across the ocular surface, but it can be inconvenient during the workday.²² Newer clear-solution formulations have been developed partly to address this issue.

Combination Therapy for Difficult Cases

Because rebamipide works primarily on the mucin layer of the tear film and has limited effect on aqueous tear production, it tends to perform best either as a standalone treatment for mucin-deficient dry eye or in combination with other agents. Case reports of patients with immune-mediated dry eye have documented marked improvements in symptoms, tear stability, and surface staining when rebamipide was combined with diquafosol, sustained over six to twelve months without side effects.²³ An updated meta-analysis echoed this idea, concluding that rebamipide is most effective as monotherapy in mucin-layer deficiency or as part of combination therapy with aqueous-enhancing or anti-inflammatory agents for broader dry eye phenotypes.²⁴

Oral Mucositis From Cancer Treatment

Radiation and chemotherapy for head and neck cancers frequently cause severe mouth sores, known as oral mucositis. These sores can be so painful that patients cannot eat or drink, sometimes forcing treatment interruptions that compromise cancer outcomes. Rebamipide gargle has been tested as a preventive and therapeutic option in this setting.

A pilot study found that 83% of patients in the placebo group developed grade 3 or higher oral mucositis (the severe kind that prevents eating), compared with about 33% in the rebamipide gargle group.²⁵ A systematic review and meta-analysis of multiple studies confirmed the association, finding significantly lower odds of severe mucositis among patients using rebamipide gargle.²⁶ A randomized trial comparing rebamipide gargle head-to-head with benzydamine (a widely used anti-inflammatory mouthwash) found the two equally effective at preventing severe mucositis, but rebamipide was superior at reducing the overall severity of radiation-induced mouth sores.²⁷

Ulcerative Colitis

A handful of small studies have explored rebamipide enemas for ulcerative colitis affecting the lower colon, including patients who had stopped responding to steroids. In one study, about 82% of steroid-resistant or steroid-dependent patients achieved remission after 12 weeks of rebamipide enemas, and most requested to continue the treatment long-term.²⁸ Another trial reported that 55% of patients with active distal ulcerative colitis reached clinical remission within three weeks of starting rebamipide enemas, and 80% showed endoscopic improvement.²⁹ A separate prospective study found significant improvements in disease activity and endoscopic scores with no serious side effects.³⁰

These results are promising for a disease that badly needs more options, but all three studies were small and none was a large randomized controlled trial. Rebamipide enemas are not established therapy for ulcerative colitis. Still, the consistent pattern of benefit across several independent groups suggests this is worth pursuing with bigger, more rigorous studies.

Side Effects and Safety

Rebamipide is generally considered well tolerated, which is part of why it has been on the market for decades without major safety scares. The oral formulation’s most commonly reported side effects are mild gastrointestinal issues. A large pharmacovigilance analysis comparing rebamipide with other drugs in the same therapeutic class found that the adverse events more frequently reported for rebamipide included indigestion, drowsiness, dry mouth, and facial swelling. None of these were serious, and the typical time to onset ranged from two to nine days.³¹

One finding that clinicians should be aware of involves older adults. The same pharmacovigilance study noted that reports of pulmonary side effects were significantly more common among patients aged 65 and older compared with younger patients. Overall, lung-related adverse events with rebamipide were uncommon, but the age-dependent signal was strong enough to warrant attention.³² In practice, rebamipide appears less likely than misoprostol to cause the cramping and diarrhea that make the latter drug hard for some patients to tolerate, which is one of the reasons rebamipide has carved out a niche in Asia’s gastroenterology practice.

For the ophthalmic form, the most notable side effect is the temporary visual blurring discussed earlier. Bitter or unusual taste can also occur if the drops drain from the eye into the back of the throat through the tear duct. Allergic reactions have been reported but are rare.

Absorption Variability

One quirk of oral rebamipide is how differently individuals absorb it. A pharmacokinetic study in healthy subjects found a two-and-a-half to three-fold variation in blood levels from person to person after the same dose. Absorption profiles often showed double peaks or a plateau rather than a smooth rise and fall, suggesting the drug interacts with efflux transporters in the gut wall that pump it back out. Genetic variation in one such transporter, MDR1, appeared to account for much of the person-to-person difference.³³ In clinical terms, this may partly explain why some trials show clear benefit while others (like the naproxen trial that showed no protection) do not: some participants may simply not absorb enough of the drug to get the full effect at a given dose.

Availability Outside Asia

Rebamipide is approved and widely prescribed in Japan, South Korea, China, India, and several other Asian countries for gastric mucosal protection. The ophthalmic formulation (Mucosta ophthalmic suspension) is approved in Japan and has become a standard option for dry eye there. In the United States and Europe, rebamipide is not approved by the FDA or EMA for any indication. Western gastroenterologists and ophthalmologists may be unfamiliar with it simply because it has never been through the regulatory process in their markets, not necessarily because the evidence is weak. For people outside Asia, access typically involves importing the drug through specialty pharmacies or encountering it while traveling or seeking care in countries where it is available.

The gap between the drug’s evidence base and its regulatory footprint in the West is one of the more striking examples of how geography shapes which therapies patients can access. Rebamipide has appeared in Asian clinical guidelines for gastroprotection and dry eye management for years, while remaining essentially unknown to most Western practitioners. Whether that changes depends on whether pharmaceutical companies see enough commercial incentive to run the large trials that Western regulators would require for approval, a decision that involves economics as much as science.

Emerging Research Beyond the Gut and Eyes

Rebamipide’s anti-inflammatory mechanism, particularly its suppression of the NF-κB pathway, has led researchers to test it in contexts well beyond its traditional uses. Lab studies have shown that it can reduce TNF-α-driven inflammation in skin cells and attenuate dermatitis severity in animal models.³ Preliminary work has even explored whether it could slow intervertebral disc degeneration, a condition driven in part by NF-κB-mediated inflammation in disc tissue.³⁴ These are early-stage findings, mostly from cell cultures and animal experiments, and none is close to becoming a clinical application. But they illustrate why rebamipide is sometimes called a “pleiotropic” drug: it touches multiple biological pathways in ways that keep opening unexpected doors for investigation.